Ultragenyx Pharmaceutical Inc. Form 8-K Summary
Business Context and Reporting Period
This Current Report on Form 8-K was filed by Ultragenyx Pharmaceutical Inc. on April 29, 2019. The report discloses the entry into a material definitive agreement regarding the company's principal executive offices located in Novato, California.
Key Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This report focuses exclusively on a lease agreement and does not contain financial performance data.
Material Changes
On April 29, 2019, the Company entered into Addendum 6 to its existing Lease with Condiotti Enterprises, Inc. Key changes include:
- Assignment of the Lease to the Company.
- Extension of the lease term to December 31, 2024.
- Coverage of space at 60 Leveroni Court, 52 Leveroni Court, and 68 Leveroni Court in Novato, CA.
Guidance, Outlook, and Risks
The filing contains no management commentary, financial guidance, or discussion of risks and contingencies beyond the execution of the lease addendum. The full text of the Addendum is referenced as an exhibit to be filed in the subsequent Quarterly Report on Form 10-Q for the period ended June 30, 2019.
Investor Verification Checklist
- Verify the specific financial terms and rent obligations within the full text of Addendum 6.
- Confirm the total square footage and specific usage rights for the three Novato locations.
- Review the upcoming Form 10-Q for the quarter ended June 30, 2019, for the official exhibit filing.